AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7593870 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cognitive treatment (CT)
Number of subjects: 34
Study 7593870 — intervention group
Group type: COMPARATOR
Intervention: Self-help support group (SG)
Number of subjects: 34
Study 7593870 — intervention group
Group type: COMPARATOR
Intervention: Symptom-monitoring waiting-list control (WL)
Number of subjects: 34
Study 1958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg
Number of subjects: 58
Study 1958108 — intervention group
Group type: COMPARATOR
Intervention: DEC 3 mg/kg
Number of subjects: 58
Study 1958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg or DEC 3 mg/kg (2 successive doses)
Number of subjects: 58
Study 1958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg or DEC 3 mg/kg
Number of subjects: 58
Study 6211296 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone, 800 mg/day
Number of subjects: 44
Study 6211296 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 30869743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 340
Study 30869743 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 340
Study 27682415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided ICBT
Number of subjects: 150
Study 27682415 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided ICBT
Number of subjects: 150
Study 27682415 — intervention group
Group type: COMPARATOR
Intervention: Guided and Unguided ICBT
Number of subjects: 150
Study 26609167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50 kIU/week)
Number of subjects: 40
Study 26609167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25432688 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 216
Study 25432688 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 216
Study 22157240 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) taken daily for 8 weeks
Number of subjects: 50
Study 22157240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22157240 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 50
Study 20569037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT)
Number of subjects: 0
Study 20569037 — intervention group
Group type: COMPARATOR
Intervention: Self-directed social support comparison intervention
Number of subjects: 0
Study 18037747 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous RF delivery
Number of subjects: 40
Study 18037747 — intervention group
Group type: COMPARATOR
Intervention: Point-by-point RF ablation
Number of subjects: 40
Study 16036193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of a mixture of 10 mL of 0.5% bupivacaine (50 mg) with epinephrine (1:500) in 40 mL of Ringer's lactate solution postoperatively (Group A)
Number of subjects: 91
Study 16036193 — intervention group
Group type: EXPERIMENTAL
Intervention: The same mixture solution infusion preoperatively and postoperatively (total 100 mg bupivacaine) (Group B)
Number of subjects: 91
Study 16036193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 91
Study 12360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Omeprazol, Fromilid (clarithromycin), and Metronidazol for 7 days followed by 2-week Omeprazol alone
Number of subjects: 20
Study 12360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Omeprazol, Fromilid (clarithromycin), and Furasolidon for 7 days followed by 2-week Omeprazol alone
Number of subjects: 20
Study 10825867 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence (10% carbamide peroxide gel)
Number of subjects: 0
Study 10825867 — intervention group
Group type: EXPERIMENTAL
Intervention: NiteWhite Excel (10% carbamide peroxide gel)
Number of subjects: 0
Study 7578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed bridge between the distal tooth of the residual dentition and an implant
Number of subjects: 23
Study 7578781 — intervention group
Group type: COMPARATOR
Intervention: Free-standing bridge on 2 implants
Number of subjects: 23
Study 7578781 — intervention group
Group type: COMPARATOR
Intervention: Implant-supported bridges
Number of subjects: 23
Study 7578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-implant fixed bridges
Number of subjects: 23
Study 2154154 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI (4 puffs, 800 micrograms of radiolabeled fenoterol)
Number of subjects: 21
Study 2154154 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (1.75 ml, 1,750 micrograms of radiolabeled fenoterol solution)
Number of subjects: 21
Study 6814282 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with two timothy major allergens, 19, 25, or partially purified timothy extract
Number of subjects: 40
Study 31438986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 12 mg/kg IV every 2 weeks (Q2W)
Number of subjects: 11
Study 28177691 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2.5 mg/kg
Number of subjects: 10
Study 28177691 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5.0 mg/kg
Number of subjects: 10
Study 26505184 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer workshops (TTT)
Number of subjects: 10
Study 26505184 — intervention group
Group type: COMPARATOR
Intervention: Written implementation guideline (GL)
Number of subjects: 10
Study 23720124 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 51
Study 23720124 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 51
Study 23720124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection with local corticosteroids
Number of subjects: 51
Study 21540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 432
Study 21540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 100 mg
Number of subjects: 432
Study 21540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 200 mg
Number of subjects: 432
Study 21540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 432
Study 21540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50+50+25+25 mg)
Number of subjects: 432
Study 21540198 — intervention group
Group type: COMPARATOR
Intervention: Colchicine 0.5 mg
Number of subjects: 432
Study 19735403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope
Number of subjects: 10
Study 19735403 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 10
Study 17517066 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 1122
Study 17517066 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 1122
Study 17517066 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1122
Study 16413334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose abdominal computed tomography (LDCT)
Number of subjects: 139
Study 16413334 — intervention group
Group type: COMPARATOR
Intervention: Abdominal plain film (APF)
Number of subjects: 139
Study 15205246 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine purite 0.15% given twice daily
Number of subjects: 33
Study 15205246 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% given twice daily
Number of subjects: 33
Study 11087239 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin administration (subgroup 1B, n = 7)
Number of subjects: 24
Study 11087239 — intervention group
Group type: EXPERIMENTAL
Intervention: No doxazosin administration (subgroup 1A, n = 7)
Number of subjects: 24
Study 11087239 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (group 2, n = 10)
Number of subjects: 24
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion for 12 to 18 hours after intervention
Number of subjects: 4010
Study 8922160 — intervention group
Group type: COMPARATOR
Intervention: No heparin infusion
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial sheath removal 12 to 18 hours after angioplasty
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial sheath removal more than 18 hours after angioplasty
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer to ICU after angioplasty
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of CareMAPs or care plans for standardization of care
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete bed rest for patients after angioplasty
Number of subjects: 4010
Study 8922160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest for an additional 6 hours after sheath removal
Number of subjects: 4010
Study 1343613 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg b.i.d. lovastatin (Mevacor)
Number of subjects: 270
Study 1343613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 4052861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study 4052861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/2% lidocaine
Number of subjects: 45
Study 4052861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/2% lidocaine/1:100 000 epinephrine
Number of subjects: 45
Study 4052861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 31144304 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARÎ´ agonist GW501516
Number of subjects: 0
Study 31144304 — intervention group
Group type: COMPARATOR
Intervention: PPARÎ´ antagonist GSK0660
Number of subjects: 0
Study 31144304 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid (PA)
Number of subjects: 0
Study 31144304 — intervention group
Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 0
Study 31144304 — intervention group
Group type: COMPARATOR
Intervention: DHFR siRNA or methotrexate
Number of subjects: 0
Study 31144304 — intervention group
Group type: COMPARATOR
Intervention: EC-specific Ppard knockout
Number of subjects: 0
Study 28794207 — intervention group
Group type: EXPERIMENTAL
Intervention: DI + walking (2.5 h/wk)
Number of subjects: 82
Study 28794207 — intervention group
Group type: COMPARATOR
Intervention: DI only
Number of subjects: 82
Study 28794207 — intervention group
Group type: EXPERIMENTAL
Intervention: DI + walking
Number of subjects: 82
Study 26291962 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg daily)
Number of subjects: 46
Study 26291962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26291962 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 46
Study 23863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualistic behavior
Number of subjects: 0
Study 23863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualistic gestures
Number of subjects: 0
Study 23863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritual with delay
Number of subjects: 0
Study 23863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing a ritual oneself
Number of subjects: 0
Study 23863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituals
Number of subjects: 0
Study 21751945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 455
Study 21751945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 20359087 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea syndrome (OSAHS)
Number of subjects: 110
Study 20359087 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snoring
Number of subjects: 110
Study 20359087 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea syndrome (OSAHS) with abnormal behavior
Number of subjects: 110
Study 20359087 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snoring with abnormal behavior
Number of subjects: 110
Study 17465970 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 10 mg/kg
Number of subjects: 180
Study 17465970 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 20 mg/kg
Number of subjects: 180
Study 17465970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg i.v.
Number of subjects: 180
Study 17465970 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, Paracetamol, and Placebo with Pethidine
Number of subjects: 180
Study 15712772 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach to teaching in CME programs
Number of subjects: 0
Study 11257737 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotic (n = 24)
Number of subjects: 108
Study 11257737 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of antibiotics (n = 35)
Number of subjects: 108
Study 11257737 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of antibiotics (n = 31)
Number of subjects: 108
Study 11257737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving antibiotics)
Number of subjects: 108
Study 9439944 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (1 g per day) for 8 weeks
Number of subjects: 22
Study 9439944 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (10 mg per day) for 8 weeks
Number of subjects: 22
Study 7944702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 40
Study 7944702 — intervention group
Group type: COMPARATOR
Intervention: Ventricular fibrillation with intermittent ischemia
Number of subjects: 40
Study 2827920 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (1% nasal spray)
Number of subjects: 54
Study 2827920 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 29079391 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation intervention
Number of subjects: 0
Study 29079391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity strategies for intervention
Number of subjects: 0
Study 28803502 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine
Number of subjects: 352
Study 28803502 — intervention group
Group type: COMPARATOR
Intervention: 20 µg recombinant hepatitis B vaccine
Number of subjects: 352
Study 26646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex ®)
Number of subjects: 40
Study 26646213 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 40
Study 26646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 22952303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention ward
Number of subjects: 152
Study 22952303 — intervention group
Group type: COMPARATOR
Intervention: Control ward
Number of subjects: 152
Study 21559935 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in subjects with high Gleason Score (GS)
Number of subjects: 70
Study 21559935 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat mass
Number of subjects: 70
Study 21559935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 70
Study 21559935 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition and leptin relation to PCa aggressiveness
Number of subjects: 70
Study 21559935 — intervention group
Group type: COMPARATOR
Intervention: Body mass index and percentage of body fat mass
Number of subjects: 70
Study 18439560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with combined primary posterior capsulorhexis and posterior optic buttonholing
Number of subjects: 50
Study 18439560 — intervention group
Group type: COMPARATOR
Intervention: In‐the‐bag IOL implantation
Number of subjects: 50
Study 16529860 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic exposure
Number of subjects: 24
Study 16529860 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 24
Study 15223814 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.08 microg/kg/min, 0.16 microg/kg/min, 0.32 microg/kg/min)
Number of subjects: 14
Study 10941943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy
Number of subjects: 3703
Study 10941943 — intervention group
Group type: COMPARATOR
Intervention: TURB alone
Number of subjects: 3703
Study 9311953 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal
Number of subjects: 404
Study 9311953 — intervention group
Group type: COMPARATOR
Intervention: Control cereal (≤3 g soluble fiber/d)
Number of subjects: 404
Study 1304806 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-polishing unit
Number of subjects: 46
Study 1304806 — intervention group
Group type: COMPARATOR
Intervention: Pumice and water
Number of subjects: 46
Study 1304806 — intervention group
Group type: COMPARATOR
Intervention: No cleaning
Number of subjects: 46
Study 2859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg thrice daily
Number of subjects: 24
Study 2859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 7.5 mg twice daily
Number of subjects: 24
Study 2859185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30368489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (app)
Number of subjects: 39
Study 30368489 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated as usual, without the app)
Number of subjects: 39
Study 27897469 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus coaching
Number of subjects: 94
Study 27897469 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study 24717369 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised C-reactive protein (CRP; >5 mg/L)
Number of subjects: 181
Study 24717369 — intervention group
Group type: EXPERIMENTAL
Intervention: Early convalescence
Number of subjects: 181
Study 24717369 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescence
Number of subjects: 181
Study 24717369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified relative dose response values
Number of subjects: 181
Study 24717369 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of anemia and vitamin A deficiency
Number of subjects: 181
Study 23189986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard gum shield‐aided intubation
Number of subjects: 80
Study 23189986 — intervention group
Group type: COMPARATOR
Intervention: Left paraglossal intubation
Number of subjects: 80
Study 19946671 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP)
Number of subjects: 66
Study 19946671 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) prosthesis (Genesis II)
Number of subjects: 66
Study 19946671 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP) in FB-CR subgroup
Number of subjects: 66
Study 19946671 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing cruciate retaining (FB-CR) prosthesis
Number of subjects: 66
Study 19946671 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP) in FB-PS subgroup
Number of subjects: 66
Study 19946671 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing posteriorly stabilized (FB-PS) prosthesis
Number of subjects: 66
Study 18279985 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyFix (BF) system with abdominal compression
Number of subjects: 32
Study 18279985 — intervention group
Group type: COMPARATOR
Intervention: VacLok (VL) immobilization device
Number of subjects: 32
Study 16651498 — intervention group
Group type: EXPERIMENTAL
Intervention: Single follow-up clinic visit focusing on asthma self-monitoring and management, environmental modification and trigger control, and linkages and referrals to ongoing care.
Number of subjects: 488
Study 16651498 — intervention group
Group type: EXPERIMENTAL
Intervention: Single follow-up clinic visit
Number of subjects: 488
Study 14709290 — intervention group
Group type: EXPERIMENTAL
Intervention: topical betaxolol 0.5% solution
Number of subjects: 34
Study 14709290 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 10870778 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral azithromycin 1 g
Number of subjects: 131
Study 10870778 — intervention group
Group type: COMPARATOR
Intervention: Seven-day doxycycline 100 mg twice daily
Number of subjects: 131
Study 9586517 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Low-Level Laser therapy (830 nm Ga‐Al‐As Laser, 4 joules, 3 sessions)
Number of subjects: 20
Study 9586517 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Low-Level Laser therapy
Number of subjects: 20
Study 9586517 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 8436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril 0.5 mg, 1 mg, or 2.5 mg
Number of subjects: 16
Study 8436152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3464039 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (single dose)
Number of subjects: 0
Study 29908319 — intervention group
Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations < 5pg/mL
Number of subjects: 197
Study 29908319 — intervention group
Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations 5 to 9pg/mL
Number of subjects: 197
Study 29908319 — intervention group
Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations > 9pg/mL
Number of subjects: 197
Study 27965852 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention for chiropractors
Number of subjects: 150
Study 27965852 — intervention group
Group type: COMPARATOR
Intervention: Printed copy of the guideline
Number of subjects: 150
Study 23369009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified foot wear (sandal)
Number of subjects: 70